We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Escitalopram and Depression in Elderly Alzheimer's Patients

This study has been terminated.
(Dr. Rabheru left VCH last year and the study was cancelled according to his research coordinator.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00488670
First Posted: June 20, 2007
Last Update Posted: June 6, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
University of British Columbia
June 18, 2007
June 20, 2007
June 6, 2011
December 2010
June 2011   (Final data collection date for primary outcome measure)
Change in Cornell Scale for Depression in Dementia (CSDD) from baseline.
Same as current
Complete list of historical versions of study NCT00488670 on ClinicalTrials.gov Archive Site
Montgomery-Åsberg Depression Rating Scale; Neuropsychiatric Inventory; Alzheimer's Disease Cooperative Study
Same as current
Not Provided
Not Provided
 
Escitalopram and Depression in Elderly Alzheimer's Patients
An Open-label Study of Escitalopram in the Treatment of Major Depressive Disorder in Elderly Patients With Alzheimer's Disease
To investigate the effect of Escitalopram in a large and diverse of dementia patients suffering from depression.
This study will assess the efficacy, tolerability, and safety of escitalopram in the treatment of Major Depressive Disorder in patients with Alzheimer's disease over a 24-week period. It will also assess the efficacy and tolerability of escitalopram after 12 weeks of treatment.
Interventional
Phase 3
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Depressive Disorder
Drug: Escitalopram
See Detailed Description.
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
50
June 2011
June 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • > 50 years
  • Male & female
  • Alzheimer's disease
  • Depressive episode
Sexes Eligible for Study: All
50 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
 
NCT00488670
H07-00050
No
Not Provided
Not Provided
Dr. Kiran Rabheru, University of British Columbia
University of British Columbia
Not Provided
Principal Investigator: Kiran Rabheru, MD University of British Columbia
University of British Columbia
June 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP